About Us

Leadership Team

Our senior management team’s leadership and vision are critical to the company’s operational efficiency and growth, positioning us well to continue bringing important therapeutics to patients in need.

William K. Heiden
President and Chief Executive Officer
William Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer and president of AMAG since...
William Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer and president of AMAG since May 2012. Mr. Heiden joined AMAG from GTC Biotherapeutics, Inc. (now rEVO Biologics, Inc.), where he was president and chief executive officer from 2010 to 2012 and chairman of the board of directors from 2007 to 2013. From 2004 to 2008, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals. Prior to that, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (now GlaxoSmithKline plc). Mr. Heiden also held various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. He currently serves on the board of directors for Atara Biotherapeutics, Inc. Mr. Heiden holds a Bachelor of Arts degree from the University of Florida, a Master of Information Management from the University of Louvain, and a Master of Business Administration from Cornell University’s Johnson Graduate School of Management.
Elizabeth Bolgiano
Executive Vice President, Chief Human Resources Officer
Elizabeth Bolgiano is an experienced human resources professional who joined AMAG in January 2014 as senior vice president of human...
Elizabeth Bolgiano is an experienced human resources professional who joined AMAG in January 2014 as senior vice president of human resources. Ms. Bolgiano joined AMAG from Thermo Fisher Scientific where she was senior vice president of human resources and a member of the executive team. Prior to Thermo Fisher Scientific, Ms. Bolgiano served as group human resources director of Smith & Nephew Company. From 1989 to 2004, Ms. Bolgiano progressed through various positions of increasing responsibility at Bristol-Myers Squibb Company. She holds Master of Business Administration and Bachelor of Science degrees from Cornell University.
J. Alan Butcher
Executive Vice President & Chief Business Officer
Alan Butcher serves as AMAG’s executive vice president and chief business officer. He joined AMAG in April 2018 and brings more than 20...
Alan Butcher serves as AMAG’s executive vice president and chief business officer. He joined AMAG in April 2018 and brings more than 20 years of extensive technical, scientific, strategic, and business development experience from large and medium-sized pharmaceutical companies. He joins AMAG from Purdue Pharma where he served as senior vice president, licensing and business development. Prior to Purdue, he led a global business development team and was responsible for identifying, evaluating and negotiating expansion opportunities at Shire Pharmaceuticals. Mr. Butcher holds a Bachelor’s of Science in Clinical Microbiology and a Master’s of Science in Biology with a concentration in Molecular Biology and Genetics from West Chester University of Pennsylvania. He is also a graduate of Cornell University’s Johnson Graduate School of Management.
Nicholas Grund
Executive Vice President and Chief Commercial Officer
Nicholas Grund serves as AMAG’s executive vice president, and chief commercial officer. He joined AMAG in January 2016 and brings more...
Nicholas Grund serves as AMAG’s executive vice president, and chief commercial officer. He joined AMAG in January 2016 and brings more than 20 years of commercial leadership experience in the biopharmaceutical industry, including several global senior-level executive roles in sales and marketing. He joins AMAG from Genzyme Corporation, a Sanofi Company, where he spent the past 13 years in business leadership roles, most recently as the leader of the company’s rare disease and multiple sclerosis franchises in Asia Pacific and Canada. Mr. Grund joined Genzyme from Bayer Diagnostics where he progressed through a number of senior finance roles in the critical care business unit from 1995 to 2002. Mr. Grund holds a Bachelor of Science degree in business administration from the University of Massachusetts and a Master of Business Administration degree from Northeastern University.
Julie Krop, M.D.
Executive Vice President, Chief Medical Officer
Julie Krop, M.D. serves as AMAG’s chief medical officer and executive vice president of clinical development and regulatory affairs. She...
Julie Krop, M.D. serves as AMAG’s chief medical officer and executive vice president of clinical development and regulatory affairs. She joined AMAG in June 2015 and has more than 15 years of experience in drug development. Dr. Krop most recently worked for Vertex Pharmaceuticals, where she served as vice president of clinical development. She began her career in the biopharmaceutical industry in 1991 at Pfizer, Inc. and has since held various leadership positions at Stryker Regenerative Medicine, Peptimmune, and Millennium Pharmaceuticals. Dr. Krop received a Bachelor of Science degree from Brown University and a medical degree from the Brown University School of Medicine. She completed her residency in the Department of Medicine at Georgetown University Hospital and a fellowship in the Department of Endocrinology at The Johns Hopkins University School of Medicine. In addition, Dr. Krop was a Robert Wood Johnson Foundation Clinical Scholar.
Edward (Ted) Myles
Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Ted Myles joined AMAG in 2016 and brings more than 20 years of public and private corporate finance and operational experience in the...
Ted Myles joined AMAG in 2016 and brings more than 20 years of public and private corporate finance and operational experience in the biotechnology, pharmaceutical and medical device industries. Prior to joining AMAG, he served in various positions at Ocata Therapeutics, Inc., most recently as chief financial officer and chief operating officer. During his tenure at Ocata, he led the turnaround of the company, which ultimately resulted in its acquisition by Astellas Pharma in February 2016. From 2008 to 2013, Mr. Myles served as chief financial officer and vice president of operations at PrimeraDx, Inc. Prior to that, Mr. Myles was senior vice president of finance and chief financial officer of Pressure Biosciences, Inc. and also served as controller at EMD Pharmaceuticals, Inc., a wholly-owned subsidiary of Merck KGaA. Earlier in his career, Mr. Myles was an associate in the healthcare investment banking group at SG Cowen Securities Corporation and served as corporate controller for Boston Biomedica, Inc. Mr. Myles became a certified public accountant in 1996 and began his career in 1993 at PriceWaterhouseCoopers LLP. Mr. Myles holds a Bachelor of Science degree in Business Administration from the University of Hartford and a Master of Business Administration from John M. Olin School of Business at Washington University.
Joseph D. Vittiglio
Executive Vice President, General Counsel, Quality & Corporate Secretary

Joseph Vittiglio serves as AMAG’s executive vice president, general counsel and quality and corporate...

Joseph Vittiglio serves as AMAG’s executive vice president, general counsel and quality and corporate secretary. Before joining AMAG, he served as vice president of legal affairs and a member of the management committee at Flexion Therapeutics, Inc. Prior to that, Mr. Vittiglio was the general counsel of AVEO Pharmaceuticals and the director of legal affairs at Oscient Pharmaceuticals Corporation. He began his legal career as an associate attorney at Gaffin & Krattenmaker, P.C., before joining Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC as a senior attorney in 1998. Mr. Vittiglio holds a Bachelor of Science degree in international relations from Tufts University and a Juris Doctor from Northeastern University School of Law.